Journal
INTERNAL MEDICINE JOURNAL
Volume 44, Issue 5, Pages 433-440Publisher
WILEY
DOI: 10.1111/imj.12407
Keywords
prostate cancer; prostate-specific antigen (PSA); screening; risk assessment; monitoring
Categories
Ask authors/readers for more resources
Population screening with prostate-specific antigen (PSA) for detection of prostate cancer is a topic associated with ongoing dissent and confusion within the oncology and wider medical community. The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings. This review will summarise the evidence and current recommendations for the use of PSA in detection and management of prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available